Effect of gene variants on opioid dose, pain and adverse effect outcomes in advanced cancer: an explorative study-Reference-Cited by-同舟云学术

Effect of gene variants on opioid dose, pain and adverse effect outcomes in advanced cancer: an explorative study

Published:2023-12 Issue:18 Volume:24 Page:901-913
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Wong Aaron K¹²³^ORCID,Klepstad Pal⁴^ORCID,Somogyi Andrew A⁵^ORCID,Vogrin Sara⁶^ORCID,Le Brian¹²^ORCID,Philip Jennifer¹²³⁷^ORCID,Rubio Justin P⁸^ORCID

Affiliation:

1. Peter MacCallum Cancer center, 305 Grattan St, Melbourne, Victoria, 3000, Australia

2. The Royal Melbourne Hospital, 300 Grattan St, Parkville, Victoria, 3050, Australia

3. Department of Medicine, University of Melbourne Eastern Hill Campus, Victoria Parade, Fitzroy, Victoria, 3065, Australia

4. Department Intensive Care Medicine, St. Olavs University Hospital, Trondheim, Norway

5. Professor of Clinical & Experimental Pharmacology, Discipline of Pharmacology, Faculty of Health & Medical Sciences, University of Adelaide, Adelaide, 5005, Australia

6. Department of Medicine, St Vincent's Hospital Melbourne, University of Melbourne, Victoria, Australia

7. St Vincent's Hospital, Palliative Care Service Victoria Parade, Fitzroy, Victoria, 3065, Australia

8. Principal Research Fellow Florey Institute of Neuroscience & Mental Health, 30 Royal Parade, Victoria, 3052, Australia

Abstract

Aim: Associations between gene variants and opioid net effect are unclear. We conducted an exploratory pharmacogenetic analysis of 35 gene variants and opioid response in advanced cancer. Patients & methods: This multi-center prospective cohort study included clinical data, questionnaires (pain and adverse effects) and DNA (blood). Negative binomial regression and logistic regression were used. Results: Within 54 participants, eight statistically significant associations (p = 0.002–0.038) were observed between gene variants and opioid dose, pain scores or adverse effects, the majority being within the neuroimmune TLR4 pathway ( IL1B [rs1143634], IL2 [rs2069762], IL6 [rs1800795], BDNF [rs6265]) and ARRB2 pathway ( ARRB2 [rs3786047], DRD2 [rs6275]). Conclusion: Neuroimmune pathway genes may contribute to differences in opioid response in cancer and may be included in future similar studies.

Funder

Bethlehem Griffiths Research Foundation Grant

Australian & New Zealand College of Anaesthetists

National Health and Medical Research Council Postgraduate Scholarship

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs-2023-0207

Reference80 articles.

1. Cancer Pain Treatment Strategies in Patients with Cancer

2. Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network

3. The Role of Pharmacogenomics in Opioid Prescribing

4. Association of ABCB1/MDR1 and OPRM1 Gene Polymorphisms With Morphine Pain Relief